Revista Brasileira Ginecologia e Obstetrícia · 2019 · 17 citations · 15 references
MedicineGynecologyOncologyGynecologic OncologyReproductive MedicineReproductive PathologyGynecologic Oncology SurgeryGynecologic PathologyOvarian CancerOvarian DisordersOvarian NeoplasiaOvarian PathologyLeydig Cell TumorsMalignant Ovarian NeoplasmsMalignant Ovarian TumorsOvarian Cancer TreatmentSertoli Cell Tumors
OBJECTIVE: To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). METHODS: Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. RESULTS: The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presented with virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0-2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation of Gynecology and Obstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of them underwent 3 cycles of paclitaxel and carboplatin every 21 days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. CONCLUSION: Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred.
15
Paul A. Harris, Robert Taylor, Robert J. Thielke et al. · Journal of Biomedical Informatics · 2008 · 51.7K citations · Full text
Sertoli-leydig cell tumors: A clinicopathologic study of 34 cases
Lawrence M. Roth, M. C. Anderson, A. D. T. Govan et al. · Cancer · 1981 · 160 citations · Full text
A clinicopathological analysis of 40 cases of ovarian Sertoli–Leydig cell tumors
Ting Gui, Dongyan Cao, Keng Shen et al. · Gynecologic Oncology · 2012 · 142 citations · Full text
Patterns of spread and recurrence of sex cord-stromal tumors of the ovary
Melissa M. Thrall, Pamela J. Paley, Ellen S. Pizer et al. · Gynecologic Oncology · 2011 · 109 citations